Abstract 2163P
Background
In France, cancer is the leading cause of death among men and the second leading cause among women. Currently, supportive care provided to cancer patients in community pharmacies are heterogeneous across the country. In order to structure and standardize pharmaceuticalsupportfor all cancer patients in primary care, TotumLab foundation has created the OncoPharma certification.
Methods
The OncoPharma certification is based on a framework that covers the activities of dispensing treatments andsupportingcancer patients, caregivers and relatives, from the time of diagnosis, during and after cancer, by the entire pharmacy team. The framework presents certified characteristics, the way to implement them, as well as documentary ressources and requested internal controls to ensure compliance. The development of the certification framework is the result of a multidisciplinary collaborative effort, bringing together all healthcare professionals involved in cancer patients care. The OncoPharma certification is accessible to all community pharmacies in France.
Results
In the certification framework, patient care is structured around 14 operational characteristics that are proposed and adapted to each individual situation. Since June 2022, the OncoPharma certification framework has been accredited by the French accreditation committee (COFRAC). This document allowed for the publication of the first clinical guideline for the management of cancer patients in community pharmacies by the Francophone Association of Supportive Oncology Care (AFSOS). As of April 2023, two pharmacies have been certified under OncoPharma, and over 40 others are in the process of certification.
Conclusions
This innovative project is the result of collective and multidisciplinary work to improve the quality of life of patients living with cancer. It promotes communication and coordination among healthcare professionals, as well as training and upskilling of pharmacy teams. This project is part of the continuous improvement and value creation in healthcare. Thanks to the Oncopharma certification, the community pharmacist plays a central role in the care of people with cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
TotumLab.
Funding
TotumLab.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2204P - Clinical predictors and inflammatory markers for malignant pleural mesothelioma prognosis: A retrospective study in a Spanish Medical Oncology Unit
Presenter: Mora Guardamagna
Session: Poster session 07
2205P - Tumor-infiltrating lymphocytes score possesses a relation with adjuvant chemo-immunotherapy benefit and cellular morphology in large-cell neuroendocrine carcinoma
Presenter: Zhiwen Luo
Session: Poster session 07
2207P - Mainstream germline genetic testing in routine oncological care of EGFR mutant non-small cell lung cancer in the United Kingdom
Presenter: Hazel O'Sullivan
Session: Poster session 07
2208P - The single-cell proteomic landscape of pulmonary lymphoepithelioma-like carcinoma
Presenter: Chi Cho
Session: Poster session 07
2209P - Mutational status of non-small cell lung cancer in Portugal: A multicentric study
Presenter: Joana Duarte
Session: Poster session 07
2210P - Reprogramming of pyrimidine metabolism drives tumorigenesis in NF2-deficient malignant pleural mesothelioma
Presenter: Duo Xu
Session: Poster session 07
2234P - Local immune-related adverse events (irAEs) are more common in tumor-bearing organs
Presenter: Steve Blum
Session: Poster session 07
2235P - Chemotherapy priming leads to hypermutability and immune surveillance in colorectal cancer
Presenter: Pietro Paolo Vitiello
Session: Poster session 07
2236P - MHC-II neoantigens and copy number alterations (CNA) drive immune checkpoint inhibitor (ICI) response in metastatic melanoma (MM)
Presenter: Benjamin Shum
Session: Poster session 07